Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis

#1772

Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.

Aim(s): To assess the expression of sst5MD4 in GEP-NETs, and evaluate its association with different pathways involved in GEP-NETs tumorigenesis.

Materials and methods: Fresh-frozen tumour samples were collected from 40 patients and analysed for expression of mRNA transcripts by quantitative real-time-PCR included somatostatin receptors and sst5TMD4, death-domain associated protein(DAXX), transcriptional regulator ATP-dependent helicase(ATRX), multiple endocrine neoplasia(MEN1), Notch and angiogenic factors (VEGFR, angiopoietin(Ang)1, Ang2, Tie2, hypoxia inducible factors and thrombospondin (THBS). Tumor characteristics: pNETs/GI-NETs: 50%/50%; G1-G2: 40%-60%; TNM stage: I(17%), II(3%), III(20%), IV(47%); 20% were functioning tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Diaz Perez A, Martínez-Fuentes A, García-Carbonero R, Luque R, Jimenez-Fonseca P,

Keywords: somatostatin receptor, neuroendocrine tumors,

To read the full abstract, please log into your ENETS Member account.